Why Did China's $22B National Fund Back Him? Decoding Lu Xiaobo’s 'Non-Consensus' Investment Logic in Healthcare

Lu Xiaobo is a rare healthcare investor who has been deeply rooted in the front lines of the pharmaceutical industry for many years. This experience has shaped his unique demeanor: he possesses the keen market intuition of a top-performing pharmaceutical sales executive, combined with the global perspective of a partner at a leading investment firm; he adheres to a steady strategy of "striving for leadership through careful positioning," while also having the courage to make decisive bets amidst "non-consensus" opportunities.

These qualities have further given rise to Lu Xiaobo’s straightforward yet resolute investment methodology: closely aligning with national strategic directions, conducting in-depth on-the-ground industry research, and integrating the principles of self-reliance and controllability in hard technology as well as high-end domestic substitution into his investment logic.

This is precisely the core reason why Hongchuang Capital has gained recognition from state-backed investors amid a divergent fundraising landscape. “First, its projects and philosophy are highly aligned; second, its investment direction and logic have been validated as correct by national-level capital.”

Immersed in the healthcare industry for nearly 30 years as both an industry professional and an investor,He has always believed that short-term fluctuations in the secondary market will not interfere with the judgment of long-term value. “The healthcare sector requires long-term commitment; the true test for investors is to find the right team at the right time.”

Hongchuang Capital has continued Lu Xiaobo’s investment thesis. As of early 2026, Hongchuang Capital’s portfolio had become a clear roadmap for tackling core challenges in China’s hard-tech healthcare sector:

• SMARTBEAM: The sole domestic innovation leader that has broken through the "chokehold" technology of liquid metal CT X-ray tubes;

• BIODALS: The Only Approved Domestic Artificial Vessel, Breaking Import Monopoly as an Innovative Medical Device Enterprise;

• Tiankai Biotech: An Innovation Leader in Overcoming the "Chokehold" Technology of Milk Proteins in Infant Formula;

• Medic: The Hidden Champion in the Niche Sector of Laboratory Automation;

• Visual Perception: The global leader in the AI ultrasound field, and the only one to have successfully achieved commercial implementation;

• Gaoguang Pharmaceutical: An innovative pharmaceutical newcomer with a globally first-in-class highly selective dual TYK2/JAK1 inhibitor, having filed its listing application with the Hong Kong Stock Exchange.

These enterprises do not chase fleeting trends or pile up buzzwords; instead, they share a highly consistent characteristic: they directly confront import monopolies to address critical “chokepoint” needs. Their teams have been deeply entrenched in the industry for over a decade, demonstrating pragmatism and diligence. With technical risks largely mitigated, these companies are approaching break-even and entering an accelerated phase of commercialization. This aligns profoundly with the national strategic directive to “invest early, invest in small ventures, invest for the long term, and invest in hard technology.”

Lu Xiaobo refers to this approach as “non-consensus” investing: “Classic investment cases are often not widely favored at the time of execution, which is where the value of information asymmetry and cognitive disparity lies.”

This “non-consensus” capability stems from Lu Xiaobo’s unique career trajectory: as the top scorer in his province’s college entrance examination, he was admitted to Zhejiang University to major in Biochemical Engineering. Inspired by Deng Xiaoping’s 1992 Southern Tour speeches, he moved south to Shenzhen after graduation and joined Sanjiu Pharmaceutical, then at the peak of its success, where he became the top sales performer within four years. He later pursued a full-time International MBA at Tsinghua University. During the first “golden decade” of the pharmaceutical industry, he transitioned into a healthcare investor, rising from investment manager to healthcare partner in just three and a half years. His distinctive investment style, coupled with a string of high-profile successful investments, earned him the favor of Sequoia China, where he ultimately became a Healthcare Partner.

The five years at Sequoia coincided with a period of explosive growth in China’s healthcare industry, and also marked the five years during which Lu Xiaobo achieved a systematic leap in his capabilities.“At Sequoia, I completed a systematic upgrade from RMB funds to USD funds, and from early-stage investing to full-cycle coverage.”

More importantly, during his tenure at Sequoia, Lu Xiaobo leveraged a global perspective built on continuous tracking of cutting-edge technological advancements both domestically and internationally, combined with his hands-on experience delving into the “capillaries” of China’s healthcare market while at Sanjiu Pharmaceutical. This enabled him to gain profound insights into industry trends—embracing both the broad overview and minute details—and accurately identify entrepreneurs with the potential to build “great companies.” It also shaped his ultimate framework for evaluating technologies: first, whether the sector aligns closely with national innovation priorities and urgent clinical needs; second, whether the team can efficiently translate innovations into commercial success.

This is precisely where the distinction in Lu Xiaobo’s investment style lies:Bearing a strong imprint of commercialization—Not necessarily the first to dare, but the one with the clearest vision, the fastest pace, and the last laugh.This aligns perfectly with the philosophy of his Zhejiang University alumnus, Duan Yongping: “Dare to be last, yet strive to be first among the latecomers.”

In a sense, “late” is not necessarily a bad thing. Lu Xiaobo may be among the last wave of well-known investors in the healthcare investment circle to embark on entrepreneurship. “Fundraising at that time was hardly an opportune moment,” Lu admitted candidly. However, the other side of the coin is that when healthcare investment stands at the delicate juncture between “expected recovery” and “actual volatility,” it is precisely the optimal time for investment firms to structure their portfolios, as “industry valuations have returned to rational levels.”

Of course, under the prevailing trend, what supports Lu Xiaobo in making “non-consensus” bets is a rigorous, down-to-earth, and highly personalized methodology.

Lu Xiaobo distilled his “non-consensus” decision-making into a twelve-character methodology: “Identify talent in subtle details, verify conduct through meticulous observation, and prioritize business substance.” This three-dimensional framework was progressively refined through classic cases such as InnoCare Pharma, Betta Pharmaceuticals, Nanomicro Tech, and Tinavi Medical Technologies.

His investment in Innovent Biologics stands as a landmark case in his career.

In 2011, Lu Xiaobo first met Yu Dechao and was deeply impressed by his determination and resilience in “achieving great things.” Due to stage restrictions of the fund at that time, he was unable to invest initially, but he continued to track the company’s progress, witnessing Innovent fulfill each step: introducing strategic resources, advancing external collaborations, building a core pipeline, and betting on PD-1 research and development. With every promise delivered and every goal achieved, Innovent perfectly aligned with the standard of “verifying actions through attention to detail.”

In 2015, Innovent initiated a new round of financing, and Lu Xiaobo decisively invested. By 2018, having joined Sequoia Capital, he once again facilitated Sequoia’s $60 million investment as the largest cornerstone investor in Innovent Biologics’ Hong Kong IPO, setting a record for Sequoia Healthcare’s largest single investment. This investment ultimately yielded returns exceeding billions, becoming an industry classic.

In retrospect, the “non-consensus” decision made on that investment validated the importance of Lu Xiaobo’s methodology of “prioritizing commerce grounded in reality.”

At that time, the primary valuation anchor for industry players and investors regarding Innovent Biologics’ 3–5-year performance expectations was the value release curve of its PD-1 inhibitor. While a multi-billion-dollar market size for PD-1 inhibitors had become an industry consensus, Lu Xiaobo still needed to address two key questions before betting on Innovent prior to its Hong Kong IPO: First, could Innovent emerge as a major player in this field within the Chinese market? Second, given that Innovent had filed only one indication for sintilimab injection—relapsed or refractory classical Hodgkin’s lymphoma—at the time of its listing, what would its subsequent sales trajectory look like?

For the former, Lu Xiaobo has already validated it through “meticulous verification in practice”; the key lies in the latter. Lu Xiaobo recalled that at the time, there were two logical frameworks for projecting the three-year sales trajectory of Sintilimab Injection: one was a conventional approach, with steady growth to RMB 100 million, RMB 300 million, and RMB 500 million; the other was an unconventional scenario, reaching RMB 500 million, RMB 1 billion, and RMB 2 billion. Lu Xiaobo insisted on the second set of projections.

As it turned out, the sales performance of sintilimab injection perfectly “mirrored” Lu Xiaobo’s projections. According to Lu, his prior experience as a top sales performer enabled him to see a fundamentally different market landscape. At that time, PD-1 inhibitors had already been approved in the United States for more than ten indications, including lung cancer, gastric cancer, and liver cancer. He anticipated that Innovent’s PD-1 inhibitor would rapidly expand its approved indications, suggesting that the actual market potential would be ten times greater than conservative estimates. Ultimately, sintilimab received approval for eight indications, was included in the initial batch of drugs covered by China’s National Reimbursement Drug List, and achieved sales volumes firmly within the industry’s top tier, fully validating his judgment.

“Prioritizing Pragmatic Commercialization” also enables Lu Xiaobo’s post-investment value creation to strike at the core: rather than offering superficial services, it delves into sales systems, channel strategies, KPI assessments, and incentive mechanisms to help technology-focused founders address their commercialization gaps. Smartbeam serves as a typical case of this post-investment empowerment and exemplifies Hongchuang Capital’s investment philosophy of being a “trusted ally” to entrepreneurs.

Smartbeam is a typical technology-driven innovative company. To help Smartbeam fully translate its technological advantages into commercial value, Lu Xiaobo and his team worked closely with Smartbeam’s management to establish practical annual operational objectives, cascading them down to specific functions such as sales, payment collection, and after-sales service. More importantly, through monthly progress review meetings, Lu Xiaobo and the Smartbeam team jointly diagnosed emerging issues, provided solutions, and continuously refined execution details, ultimately achieving extraordinary growth with a doubling of sales revenue.

During this process, Hongchuang not only helped SMARTBEAM introduce outstanding professional managers to enhance the overall capabilities of its sales team, but also further optimized the team’s performance evaluation and incentive systems.This demonstrates that Lu Xiaobo’s investment philosophy of “prioritizing commerce through substance” is not merely a slogan, but a comprehensive, practice-oriented empowerment strategy that permeates operations, extends to every detail, and directly addresses critical pain points.

Investments in CITIC Capital and Smartbeam serve as validating cases for Lu Xiaobo’s “non-consensus” investment strategy, but missing out on BeiGene when its valuation was only $150 million in 2014 remains the greatest regret of his investment career. Based on BeiGene’s current market capitalization of tens of billions of dollars, this would have been an investment yielding at least a hundredfold return.

In fact, long before engaging with Innovent, Lu Xiaobo had already conducted thorough due diligence on BeiGene. He immediately recognized the value of the team: John Oyler possessed top-tier global vision and capital operation capabilities, while Wang Xiaodong was a premier scientist who combined strategic perspective with pragmatism, forming an extremely rare “golden combination.” However, at that time, amid a market environment where drug approval reforms had not yet been implemented and the pathway for “global novel” drugs remained uncertain, the project was considered “non-consensus.” Due to constraints within the fund’s mechanism, he missed the investment opportunity twice.

“Many opportunities are ‘non-consensus’ in the present; whether one dares to act against the trend determines the height of investment.” Lu Xiaobo candidly stated that this is also an important motivation for him to establish Hongchuang Capital — to use his own logic to invest in the next era's star.

Lu Xiaobo rarely discusses technical gimmicks or short-term fluctuations. Hongchuang’s portfolio clearly points toward the future: long-term deep cultivation of hard technology, with a focus on domestic substitution and essential clinical needs. Smartbeam has dedicated over a decade to CT X-ray tubes, while Tiankai Biotechnology has spared no effort in achieving protein localization. These founders may lack dazzling public profiles, but they are the most resilient “pioneers” within the industry. In Lu Xiaobo’s view, addressing critical bottlenecks precisely requires this kind of decade-long perseverance.

He firmly believes that there is only one ultimate answer to navigating economic cycles: enterprises capable of addressing genuine needs at a reasonable cost and consistently generating healthy cash flows will ultimately be rewarded by time.

Looking Ahead, Lu Xiaobo Predicts Three Major Trends in Medical Investment:

First, vertical specialization has become the mainstream. Generalist funds struggle to cover the entire industry chain; only vertical funds with deep industry expertise, clinical understanding, and commercialization acumen can consistently capture high-quality opportunities.

Second, invest early, invest in small-scale ventures, and invest in hard technology, but do not invest in stories. Hongchuang focuses on the growth stage from 1 to 10, amplifying certainty and reducing unknown risks, rather than gambling on vague early-stage concepts.

Third, commercialization capability has become the core barrier to entry. Projects lacking data, application scenarios, or differentiation will gradually be phased out, while enterprises that address genuine needs and achieve domestic substitution will emerge as the primary choice for capital investment.

In terms of portfolio management, Hongchuang will selectively increase positions in high-growth projects to maximize growth dividends; the fund size will remain restrained, adhering to a boutique fund model of approximately RMB 500 million, following the strategy of “small and beautiful, deep companionship, and strong empowerment.”

In terms of the LP structure, Hongchuang’s inaugural fund brings together industry leaders, national-level guidance funds, and market-oriented capital, forming a “industry + government + market” golden combination.

In the future, Hongchuang will continue to focus on hard technology, domestic substitution, and critical bottleneck areas, uncovering more hidden champions in niche markets. Accompanying entrepreneurs to address urgent clinical needs and improve the quality of human life and health, while simultaneously building great companies, is the original intention of Lu Xiaobo as an investor embarking on an independent entrepreneurial journey, and also the vision and mission of Hongchuang Capital.

First Review | Shi Wanjia

Second Review | Li Fangchen

Third Review | Li Jingzhi